Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Sana Biotechnology shared six-month results from a first-in-human study of its islet cell therapy UP421 for type 1 diabetes. Using its hypoimmune technology, Sana transplanted cells without immunosuppression. The cells survived, produced insulin, and responded to meals with no safety issues or immune rejection.